Dear Rhonda,
Thank you very much for your email message. I must let you know straight away
that I am not a clinician - I am only a scientist.
It is my understanding that the overwhelming majority of HER2+ patients do NOT
overexpress cyclin D1. Only a small fraction of HER2+ tumors also overexpress
cyclin D1. According to only one study, these HER2+, cyclin D1-overexpressing
patients have poor survival rates. The study has not been repeated on a larger
population, and it has not been independently confirmed by other investigators.
In any case, I suggest you address your questions to a physician, not a
scientist like myself. One of the co-authors on our paper, Dr. Lyndsay Harris
from our Institute works with breast cancer patients. Her email address:
http://<font color="#800080">lyndsay...ard.edu</font>
FAX: (617) 632.3478
I hope this will be helpful.
With my very best wishes for you,
Peter Sicinski
> -- --------
> From: rhonda r hoffman
> Sent: Thursday, January 19, 2006 10:42 AM
> To: Sicinski, Peter;
http://<font color="#800080">hoffman...msn.com</font>
> Subject: Regarding article on "New cellular flaw found in some virulent
> breast cancers
>
> I am an almost 1 year Stage 1, ER/PR-, Her2+ (3.16 fish) breast cancer
> survivor and I posted the article on your recent findings on the HER2support
> group board and MANY of our group have found the 13% survival rate quite
> disturbing. Could you PLEASE give us more information on your findings AND
> or direct us on how we may obtain a copy of the study? Thank you.
>
> Rhonda Hoffman
>
> New cellular flaw found in some virulent breast cancers
>
> ------------------------------------------------------------------------------
> --
>
>
http://<font color="#800080">http://...24.html</font>
>
> Rhonda
> ***
> Posts: 117 ONlY a 13% survival over 7 years for this co expresion of her2
> and overactive cyclin
>
> ------------------------------------------------------------------------------
> --
>
> Thanks for the various links and posts on this topic of p27 and cyclin D and
> Flavinoid. What really gets me about this posted article is the following:
> "ONlY a 13% survival over 7 years for this co expresion of her2 and
> cyclinD." It is my understanding that essentially everyone that is her2+ is
> + cyclinD. These outrageous poor survival rates are discouraging to say the
> least. Let's hope this study on survival rates was small and insignificant.
> I've been looking but haven't seen the study for the 13% survival, have you?
> __________________
> Fondly,
> Robin
>
>
>
>